New combo therapy targets leukemia stem cells in MDS and AML
NCT ID NCT06548230
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-phase trial tests a new drug called nadunolimab combined with standard treatments (azacitidine, with or without venetoclax) in 40 adults with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find a safe dose and see if the combination can better target leukemia stem cells. Participants must have certain risk levels or relapsed disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.